|
| Status |
Public on Dec 21, 2023 |
| Title |
Gene expression profiling in EORTC 90111 study, a window of opportunity trial with afatinib in HNSCC |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
|
| Summary |
In the EORTC 90111, open-label, randomised, multicentre, phase II trial, patients were treated with afatinib for 14 days (day 15 until day 1) before surgery (day 0). Tumour biopsies, 2-[fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography (18-FDG PET) and magnetic resonance imaging (MRI) were performed at diagnosis and just before surgery. The main aim of the study was to identify predictive biomarkers among treatment-naive patients in this curative setting.
|
| |
|
| Overall design |
Eligible patients had to have a new histological diagnosis of HNSCC of the oral cavity, oropharynx, hypopharynx or larynx and be selected for primary curative surgery. Thirty-eight samples corresponding to paired pre- and post-treatment specimens belonging to 19 cases were profile for gene expression. The primary tumor needs to be ≥ 2 cm in their largest diameter measured bidimensionally by imaging done within two weeks prior to randomization. The primary outcome was the reduction in the tumor uptake volume as assessed by FDG-PET. The response to therapy was expressed as a continuous trait representing the change in SUVmax between the pre- and post-treatment as: ΔSUV = (SUVmax post – SUVmax pre)/SUVmax pre.
|
| |
|
| Contributor(s) |
De Cecco L |
| Citation(s) |
35121395 |
| |
| Submission date |
Dec 22, 2021 |
| Last update date |
Dec 21, 2023 |
| Contact name |
Loris De Cecco |
| E-mail(s) |
[email protected]
|
| Organization name |
IRCSS Istituto Nazionale Tumori
|
| Street address |
via Venezian 1
|
| City |
Milan |
| ZIP/Postal code |
20133 |
| Country |
Italy |
| |
|
| Platforms (1) |
| GPL14951 |
Illumina HumanHT-12 WG-DASL V4.0 R2 expression beadchip |
|
| Samples (38)
|
|
| Relations |
| BioProject |
PRJNA791613 |
Less...
More...